Biogen (BIIB) to Report Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS at American Neurological Association Annual Meeting
Go back to Biogen (BIIB) to Report Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS at American Neurological Association Annual Meeting| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 229.05 +1.45 (0.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $227.60 | 52 Week High | $333.65 | |||
| Open | $225.87 | 52 Week Low | $223.02 | |||
| Day High | $229.62 | P/E | 29.33 | |||
| Day Low | $225.51 | EPS | $7.81 | |||
| Volume | 339,458 | |||||
